Medical Writing. Sandoz, a division of Novartis, has announced that the European Commission (EC) has approved a Type II variation to add subcutaneous (sc) administration of Binocrit (epoetin alfa) in the Nephrology indication.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
